Trials
Search / Trial NCT06422572

Tissue Kallikrein Protect Against Ischemic Stroke

Launched by QIN ZHANG · May 18, 2024

Trial Information

Current as of February 08, 2025

Completed

Keywords

Stroke

ClinConnect Summary

Analyze the data of a 5-year follow-up on 2115 control individuals from the case-control study of the previous research. We completed the 5-year follow-up on this group in 2016 (whether they had a stroke, whether they are alive, and the cause of death).

Conduct a 12-year follow-up on 6487 community individuals from the previous study (whether they had a stroke within 12 years, whether they are alive, and the cause of death). We collaborated with the hospital platform's computer center to conduct follow-up through AI questionnaire surveys, followed by supplementing AI questionnaire data wit...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1) Control population in the previous stroke case-control study;
  • 2) The CHD case-control population in the previous study;
  • 3) The population in the community cross-sectional study of the previous study.
  • Exclusion Criteria:
  • Stroke patient

Trial Officials

QIN Zhang, phd

Principal Investigator

Tongji Hospital

About Qin Zhang

Qin Zhang is a dedicated clinical trial sponsor with a commitment to advancing medical research and innovation. With a focus on developing novel therapeutic solutions, the organization collaborates with leading researchers and healthcare institutions to conduct rigorous clinical trials. Qin Zhang emphasizes ethical standards, patient safety, and data integrity, ensuring that all studies adhere to regulatory requirements and best practices. By fostering a collaborative environment, Qin Zhang aims to contribute significantly to the understanding and treatment of various medical conditions, ultimately improving patient outcomes and quality of life.

Locations

Wuhan, Hubei, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0